Project Grant R01CA295874
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$524K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This federal Project Grant award, totaling $244,228.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will fund a research project led by the University of Texas MD Anderson Cancer Center to develop a functional proteomics approach for accurately mapping patient tumor samples to preclinical lung cancer models. The key objectives are to: 1) expand proteomic profiling of lung cancer patient-derived xenograft...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Texas MD Anderson Cancer Center to conduct research aimed at understanding how mutations in the TP53 tumor suppressor gene drive pro-metastatic interactions between pancreatic cancer cells and the surrounding tumor microenvironment. The $453,304 award will fund a 5-year project focused on clarifying the signaling mechanisms by which mutant TP53 activates the...
This Project Grant award of $160,330, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program, supports research to investigate the biochemical determinants of genome instability induced by eukaryotic topoisomerase II. The research aims to understand how the biochemical properties of topoisomerases, along with other factors like chromatin structure and DNA repair pathways, contribute to genome instability. Key project...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA Program 93.310 - Trans-NIH Research Support, provides $1,476,000.00 to The University of Texas Southwestern Medical Center to develop and apply innovative tools to study the role of subcellular redox circuits in tumor metastasis. The project aims to address key questions about how highly metastatic tumors overcome oxidative stress, using advanced in vivo optogenetic approaches,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on "Decoding the Metabolic Routes of Purine Nucleotides in Cancer". The overarching goal is to expand the mechanistic understanding of purine synthesis pathways in tumors and identify new strategies to target purine supply mechanisms for effective cancer treatment. Key research aims include:...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $140,130 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate the role of thiol reductive stress in lung cancer growth and metastasis. The award supports research investigating how activation of the NRF2 transcriptional regulator disrupts the NADH/NAD+ equilibrium, inducing reductive stress that blocks mitochondrial function and inhibits...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Cause and Prevention Research (CFDA 93.393), supports research to elucidate the roles and regulatory mechanisms of the protein APE1 in the ATR DNA damage response signaling pathway. The $342,569 award, effective March 1, 2025 through February 28, 2030, will enable researchers at the University of North Carolina at Charlotte to investigate how APE1 forms liquid-liquid phase separations in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...